NIH Drug Patent Licensees Would Develop ‘Access Plan’ Under Proposal; Pricing Commitments Optional

Proposed rule would not require price concessions in the interest of balancing enhanced access with protecting the ‘viability and sustainability of a product’ in the market.

NIH Seeks Input On Elements Of 'Access Plan' For Licensees • Source: Shutterstock

The National Institutes of Health is proposing to help enhance public access to drugs, biologics, vaccines and medical device products stemming from taxpayer-funded inventions by requiring that patent licensing arrangements made through its Intramural Research Program include a plan to achieve that goal.

Key Takeaways

  • NIH Intramural Research Program's proposed new licensing policy for drugs, biologics, vaccines and devices would require partners to develop a plan to promote public access to products stemming from taxpayer-funded inventions.

The plan could, but would not be required to, include ways to ensure affordability through pricing commitments, according to the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet